Officials with the FDA have approved a new dosage strength (16 milligrams/4 milligrams) of buprenorphine and naloxone sublingual film for the maintenance treatment of opioid dependence.
Top news of the day from across the health care landscape.
The new formulation is the only immune globulin available in the United States that is approved for post-exposure protection against hepatitis A and measles.
Ozanimod reduced the number of brain lesions and lowered relapse rates in patients with relapsing multiple sclerosis.
Top news of the day from across the health care landscape.
Top news of the week from Specialty Pharmacy Times.
The years of research has translated into advances outside the HIV field, including in oncology and other immune diseases.

Most Popular

Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.